| Views | |
|---|---|
| Evaluating the impact of bevacizumab as a targeted therapy in combination with standard chemotherapy on disease progression and treatment outcomes in ovarian cancer | 22 |
| November 2025 | December 2025 | January 2026 | February 2026 | March 2026 | April 2026 | May 2026 | |
|---|---|---|---|---|---|---|---|
| Evaluating the impact of bevacizumab as a targeted therapy in combination with standard chemotherapy on disease progression and treatment outcomes in ovarian cancer | 14 | 1 | 0 | 1 | 0 | 3 | 3 |
| Views | |
|---|---|
| 104-106.pdf | 1 |
| Views | |
|---|---|
| Canada | 4 |
| United States | 4 |
| Ireland | 3 |
| Russia | 2 |
| Belarus | 1 |
| Egypt | 1 |
| India | 1 |
| Vietnam | 1 |
| South Africa | 1 |
| Views | |
|---|---|
| Ottawa | 4 |
| Menlo Park | 2 |
| Moscow | 2 |
| Buffalo | 1 |
| Hanoi | 1 |
| Johannesburg | 1 |
| Minsk | 1 |
| San Diego | 1 |